GiveCrypto Donates $3.6 Million to Brink for Bitcoin Development

Source: PixabayCoinbase’s philanthropic arm GiveCrypto is donating $3.6 million to Bitcoin-supporting nonprofit Brink, according to a February 16 announcement. In an X post, Brink announced that all GiveCrypto funds would be directed exclusively to support Brink engineers and their open-source development efforts related to Bitcoin. Here’s everything you need to know. Brink is excited to...

Read More

TwyAe: A Journey of Innovation and Future Blueprint

In 2023, TwyAe Exchange embarked on a remarkable journey of growth. This year, TwyAe not only achieved a steady expansion of its user base but also strengthened its brand influence through educational initiatives and participation in international events. Each step highlighted the commitment of TwyAe to technological innovation and user experience, enhancing its image and reputation...

Read More

Bhutan Government’s BTC Transfer Sparks Speculation Amid $71K Bitcoin Surge

Bhutan’s government transferred 935 BTC ($66 million) to Binance as Bitcoin nears $71,000, fueling speculation about possible sales.Bhutan’s crypto strategy prioritizes Binance, with substantial holdings and additional assets in Ethereum and other cryptocurrencies, highlighting a robust digital asset approach. Following news of Bhutan’s Bitcoin holdings of 13,000 BTC, a recent CNF update revealed that blockchain...

Read More

Bitcoin Price Prediction: BTC Drops to $68,000, Market Cap Hits $1.3 Trillion Amidst Bearish Trend; What's Next?

Bitcoin’s current market position has sparked renewed interest in Bitcoin price prediction. Trading at $67,836.31 with a 24-hour trading volume of $42.4 billion, Bitcoin has dipped 2.27% in the last 24 hours. As the leading cryptocurrency with a market cap of $1.3 trillion, its movements are closely watched, with traders focusing on key resistance and...

Read More

Baird starts Axsome Therapeutics stock at Outperform on promising trial outlook

Tuesday, Baird initiated coverage on shares of Axsome Therapeutics (NASDAQ:AXSM), assigning the stock an Outperform rating and setting a price target of $108.00. The firm has expressed confidence in the company\'s upcoming clinical trial results, particularly for its AXS-05 drug, which is currently in phase 3 trials for Alzheimer\'s disease agitation, expected in the second...

Read More